Matches in Wikidata for { <http://www.wikidata.org/entity/Q98830178> ?p ?o ?g. }
Showing items 1 to 59 of
59
with 100 items per page.
- Q98830178 description "artículu científicu espublizáu n'agostu de 2020" @default.
- Q98830178 description "scientific article published on 28 August 2020" @default.
- Q98830178 description "wetenschappelijk artikel" @default.
- Q98830178 description "наукова стаття, опублікована 28 серпня 2020" @default.
- Q98830178 name "Patient-reported tolerability of veliparib combined with cisplatin and etoposide for treatment of extensive stage small cell lung cancer: Neurotoxicity and adherence data from the ECOG ACRIN cancer research group E2511 phase II randomized trial" @default.
- Q98830178 name "Patient-reported tolerability of veliparib combined with cisplatin and etoposide for treatment of extensive stage small cell lung cancer: Neurotoxicity and adherence data from the ECOG ACRIN cancer research group E2511 phase II randomized trial" @default.
- Q98830178 type Item @default.
- Q98830178 label "Patient-reported tolerability of veliparib combined with cisplatin and etoposide for treatment of extensive stage small cell lung cancer: Neurotoxicity and adherence data from the ECOG ACRIN cancer research group E2511 phase II randomized trial" @default.
- Q98830178 label "Patient-reported tolerability of veliparib combined with cisplatin and etoposide for treatment of extensive stage small cell lung cancer: Neurotoxicity and adherence data from the ECOG ACRIN cancer research group E2511 phase II randomized trial" @default.
- Q98830178 prefLabel "Patient-reported tolerability of veliparib combined with cisplatin and etoposide for treatment of extensive stage small cell lung cancer: Neurotoxicity and adherence data from the ECOG ACRIN cancer research group E2511 phase II randomized trial" @default.
- Q98830178 prefLabel "Patient-reported tolerability of veliparib combined with cisplatin and etoposide for treatment of extensive stage small cell lung cancer: Neurotoxicity and adherence data from the ECOG ACRIN cancer research group E2511 phase II randomized trial" @default.
- Q98830178 P1433 Q98830178-9DE99EC8-66A5-4AAF-A33B-D07A52280782 @default.
- Q98830178 P1476 Q98830178-9499DEB0-C774-43C0-A09D-7AF4A88C898F @default.
- Q98830178 P2093 Q98830178-612775C5-83EC-430D-942B-333CB4B2EF66 @default.
- Q98830178 P2093 Q98830178-6BE45E56-F9C7-4583-B850-0D59C8C99C0B @default.
- Q98830178 P2093 Q98830178-7D5C3349-3E69-4AF5-A0CB-D29DB03420CB @default.
- Q98830178 P2093 Q98830178-95E30F94-AC5E-4B48-8EFD-76922623A748 @default.
- Q98830178 P2093 Q98830178-AA07AB2D-0D70-482A-9696-5487016445B4 @default.
- Q98830178 P2093 Q98830178-BB89E52A-EF61-497B-809D-6F28655280CD @default.
- Q98830178 P2093 Q98830178-BDB6A6E8-6E1C-49EE-ABDE-AA8C625245BE @default.
- Q98830178 P2093 Q98830178-BE975440-AE55-412D-AA6C-238E08E66F45 @default.
- Q98830178 P2093 Q98830178-DCE65F53-E088-44AE-8142-4CE7ACFA7B09 @default.
- Q98830178 P2093 Q98830178-ED80E97F-E9F3-486C-80DD-EBF64C87AC82 @default.
- Q98830178 P2093 Q98830178-FB733360-06E9-4302-A169-2745F6FFF9AC @default.
- Q98830178 P2093 Q98830178-FF8160AE-93EC-487D-A7CA-0EE6083A1B54 @default.
- Q98830178 P31 Q98830178-209894AA-9A43-4773-BCF2-BA0CB19C085F @default.
- Q98830178 P356 Q98830178-ED9126FB-A970-4D78-90B0-825E364AD08B @default.
- Q98830178 P50 Q98830178-14B06EE7-B34A-49FC-869C-0325F128681E @default.
- Q98830178 P50 Q98830178-5338FF57-D184-4A81-A108-E01ABB4FEF5F @default.
- Q98830178 P50 Q98830178-99986A73-8D59-40FC-8B72-92317E2E3DE8 @default.
- Q98830178 P577 Q98830178-9E1863B5-1AD8-40B7-B721-3185B49EE2D8 @default.
- Q98830178 P698 Q98830178-8836C03C-0D65-481B-AA54-C941F2DDDBD6 @default.
- Q98830178 P921 Q98830178-18F5C727-28A4-4EBF-A829-99EAE6FC0BE3 @default.
- Q98830178 P921 Q98830178-FB45E3E8-7143-41CF-AE8A-063325192835 @default.
- Q98830178 P356 CAM4.3416 @default.
- Q98830178 P698 32860331 @default.
- Q98830178 P1433 Q27724564 @default.
- Q98830178 P1476 "Patient-reported tolerability of veliparib combined with cisplatin and etoposide for treatment of extensive stage small cell lung cancer: Neurotoxicity and adherence data from the ECOG ACRIN cancer research group E2511 phase II randomized trial" @default.
- Q98830178 P2093 "Bradley W Lash" @default.
- Q98830178 P2093 "David Cella" @default.
- Q98830178 P2093 "Fengmin Zhao" @default.
- Q98830178 P2093 "Gordan Srkalovic" @default.
- Q98830178 P2093 "James L Wade" @default.
- Q98830178 P2093 "Joseph W Leach" @default.
- Q98830178 P2093 "Josephine L Feliciano" @default.
- Q98830178 P2093 "Nisha A Mohindra" @default.
- Q98830178 P2093 "Suresh S Ramalingam" @default.
- Q98830178 P2093 "Suzanne E Dahlberg" @default.
- Q98830178 P2093 "Taofeek K Owonikoko" @default.
- Q98830178 P2093 "Ticiana A Leal" @default.
- Q98830178 P31 Q13442814 @default.
- Q98830178 P356 "10.1002/CAM4.3416" @default.
- Q98830178 P50 Q87613642 @default.
- Q98830178 P50 Q87813540 @default.
- Q98830178 P50 Q92675540 @default.
- Q98830178 P577 "2020-08-28T00:00:00Z" @default.
- Q98830178 P698 "32860331" @default.
- Q98830178 P921 Q418817 @default.
- Q98830178 P921 Q7830379 @default.